Crystal structure of sialylated IgG Fc: Implications for the mechanism of intravenous immunoglobulin therapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 38, 2013, Pages

  Crispin, Max ^a   Yu, Xiaojie ^a   Bowden, Thomas A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD209 ANTIGEN; CD23 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; SIALOPROTEIN;

CIRCULAR DICHROISM; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGLOBULIN STRUCTURE; LETTER; PRIORITY JOURNAL; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SIALYLATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; CELL ADHESION MOLECULES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LECTINS, C-TYPE; RECEPTORS, CELL SURFACE; RECEPTORS, IGE; RECEPTORS, IGG;

EID: 84884309807     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310657110     Document Type: Letter

References (5)

1. Anthony RM, Wermeling F, Karlsson MC, Ravetch JV (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci USA 105(50): 19571-19578.
2. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV (2013) General mechanism for modulating immunoglobulin effector function. Proc Natl Acad Sci USA 110(24):9868-9872.
3. Barb AW, et al. (2012) NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 51(22): 4618-4626.
4. Bowden TA, et al. (2012) Chemical and structural analysis of an antibody folding intermediate trapped during glycan biosynthesis. J Am Chem Soc 134(42):17554-17563.
5. Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN (2013) Dissecting the molecular mechanism of IVIg therapy: The interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 425(8): 1253-1258.